AstraZeneca will buy AbelZeta Pharma’s 50% share of development and commercialization rights in China for a CAR-T therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback